Roche adds data to Avastin's ovarian-cancer drive

Roche may have hit a setback in marketing Avastin as a breast cancer treatment, but it's forging ahead in developing the drug for ovarian cancer. And the company has gained more support for that push. Avastin met its goal in a new ovarian cancer trial. The Oceans study showed women given a course of chemotherapy plus Avastin, and then Avastin alone, lived longer without their cancer worsening.

The company's announcement didn't say how long Avastin boosted progression-free survival; presumably, the details will come later at a scientific conference. In one previous study, adding Avastin to the drug mix helped women survive without worsening disease for about two months--18.3 versus 16 in the chemo-only patients.

In another, the progression-free survival benefit was about four months, 14.1 months versus 10.3 months in the chemo-only patients. Those two studies looked at Avastin as a first-line treatment, while the latest one tested the drug as a second-line treatment in women whose cancer had returned.

Roche has already asked European regulators to approve Avastin for ovarian-cancer use, and it plans to ask the FDA for its blessing later this year, the company said in a statement. If the drug does end up losing its FDA approval for breast cancer--Roche has appealed that decision--then a new use in ovarian cancer might help ease the pain. Analysts aren't sure, however, whether a progression-free survival benefit will be enough to persuade regulators. And so far Avastin hasn't shown an improvement in overall survival.

- read the statement from Roche's Genentech unit
- see the Reuters coverage
- get more from the Wall Street Journal

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.